Computer models that predict liver damage from thyroid drugs could not explain why methimazole causes liver injury in some patients, meaning the model is missing key biological pathways involved in its toxicity.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether clinical reports of MMI-induced liver injury consistently occur despite low predicted risk in computational models, identifying patterns in patient characteristics or co-factors.
A systematic review and meta-analysis of all published case reports, cohort studies, and pharmacovigilance data on MMI-induced DILI, analyzing frequency, dose-response, latency, and clinical features across 5,000+ cases, comparing to PTU-induced cases.
An RCT could test whether MMI exposure triggers liver injury through pathways not modeled by DILIsym, such as immune-mediated injury or metabolite toxicity, by measuring biomarkers over time.
A double-blind RCT of 200 adults receiving MMI (30 mg/day) vs. placebo for 12 weeks, with serial measurements of liver enzymes, serum metabolites (e.g., reactive intermediates), immune markers (e.g., HLA haplotypes, cytokines), and liver biopsy in a subset with ALT >3×ULN.
A cohort study could identify whether patients developing MMI-induced liver injury share specific metabolic or genetic profiles not captured by current models.
A prospective cohort of 5,000 patients prescribed MMI for hyperthyroidism, with monthly liver enzyme monitoring and biannual collection of blood for metabolomic and genomic profiling, focusing on those who develop ALT >2×ULN.
A case-control study could determine whether patients with MMI-induced liver injury have distinct metabolic signatures or HLA variants compared to those who tolerate the drug.
A case-control study comparing 300 patients with MMI-induced ALT >2×ULN to 900 matched controls without liver injury, analyzing serum metabolites, HLA typing, and drug metabolite profiles using mass spectrometry and genomics.
A cross-sectional analysis could describe the prevalence of abnormal liver enzymes and associated biomarkers in patients currently taking MMI.
A cross-sectional survey of 3,000 adults currently taking MMI, measuring ALT, AST, bilirubin, and serum metabolites (e.g., glutathione, reactive oxygen species markers) at a single time point, excluding acute illness.